A paper published in Pharmaceutics describes development and validation of a production process for 5 mg tablets of infliximab, using biosimilar CT-P13 (Remsima, Inflectra), for the treatment of inflammatory bowel disease.
The oral delivery of biologic drugs represents an as-yet unattained goal. However, the potential benefits of oral administration of these therapies in terms of compliance, comfort, and drug storage are many, and several drug makers are pursuing the possibility: Last year, Amgen and Entera Bio announced a research collaboration into oral administration of biologics, and Protalix BioTherapeutics announced positive results from a study on oral administration of anti—tumor necrosis factor (anti-TNF) therapies.
Now, a paper published in Pharmaceutics describes development and validation of a production process for 5 mg tablets of infliximab, using biosimilar CT-P13 (Remsima, Inflectra), for the treatment of inflammatory bowel disease (IBD).
The authors of the paper hypothesized that, in IBD, targeting infliximab administration to the ileo-colonic region could be efficacious in treating local IBD inflammation.
The researchers used the biosimilar infliximab and reconstituted it into a sugar solution that, when lyophilized, yielded powder that could be further compounded and treated with a coating.
The coating technology (called ColoPulse) used on the tablets has a pH sensitive polymer; the intraluminal pH of the gastrointestinal tract rises during transit from the jejunum to the ileum, then drops in the colon, and the tablet’s coating uses this period of pH increase to disintegrate in the terminal ileum.
According to the researchers, the in vitro stability of infliximab in simulated gastrointestinal systems is “encouraging,” and analyses of infliximab content, tertiary protein structure, aggregates, and potency showed that the infliximab present in the coated tablet was stable during compounding and could bind to TNF.
Stability data showed that the preparation was stable for up to 6 months at 25°C.
The authors note that a clinical trial will be necessary to determine the such factors as the pharmacokinetics of the proposed coated tablet, as well as the potential for development of anti-drug antibodies.
Reference
Gareb B, Posthumus S, Beugeling M, et al. Towards the oral treatment of ileo-colonic inflammatory bowel disease with infliximab tablets: development and validation of the production process. Pharmaceutics. 2019;11(9):428. doi: 10.3390/pharmaceutics11090428.
HHS Praises Biosimilars Savings but Opportunities to Reduce Part B Spending Remain
November 28th 2023Although biosimilars have already generated savings for Medicare Part B programs and beneficiaries, opportunities for substantial reductions in spending remain, according to a report from the HHS.
Dr Fran Gregory Sizes Up the US Adalimumab Market: Will Biosimilars See Success?
September 17th 2023On this episode of Not So Different, Fran Gregory, PharmD, MBA, vice president of emerging therapies at Cardinal Health, analyzes the adalimumab market so far in the United States and provides insight into how the market needs to adapt to accept these products and ensure lower drug costs for patients.
Adalimumab Biosimilars Take Center Stage: A Game Changer for IBD Treatment
July 16th 2023Laura Wingate, from the Crohn's & Colitis Foundation, explains some of the challenges regarding educating patients and providers on biosimilars for inflammatory bowel disease (IBD) as well as whether the gastroenterology space is ready for the influx of adalimumab biosimilars.
Real-World Data Confirm Safety, Efficacy of CT-P13 in Inflammatory Diseases
November 9th 2023A real-world analysis from Japan confirmed that CT-P13, an intravenous infliximab biosimilar, had comparable safety and efficacy to the reference product (Remicade; infliximab) in patients with immune-mediated inflammatory diseases.
Physicians Agree on Safety of Biosimilars, Nonmedical Switching in IBD, Survey Says
November 2nd 2023An international survey found that providers agree that use of biosimilars in inflammatory bowel disease (IBD) is safe and effective in both patients who are treatment-naïve and those who are already being treated with a reference agent.